CLAIMS

What is claimed is:

1. Crystalline



2. Crystalline anhydrous



3. Crystalline anhydrous



characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 11.6, 12.4, 18.6, 19.0, 21.6 and 23.6.

4. Crystalline anhydrous



in accordance with claim 3 having the X-ray diffraction pattern substantially shown in Figure 1.

5. A pharmaceutical composition comprising: crystalline



in accordance with any one of claims 1 to 4; and a pharmaceutically acceptable excipient.

6. A method of treating bladder cancer, breast cancer, colon cancer, rectal cancer, kidney cancer, liver cancer, small cell lung cancer, non-small-cell lung cancer, esophagus cancer, gall-bladder cancer, ovarian cancer , pancreatic cancer, stomach cancer, cervix cancer, thyroid cancer, prostate cancer, squamous cell carcinoma, melanoma, acute lymphocytic leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkett's lymphoma, acute myelogenous leukemia, chronic myelogenous leukemia, endometrial cancer, head and neck cancer, glioblastoma, osteosarcoma, or rhabdomyosarcoma, the method comprising administering to a patient in need thereof, a therapeutically acceptable amount of a pharmaceutical composition comprising crystalline



in accordance with any one of claims 1 to 4.

7. The compound



8. The compound



9. Crystalline



10. Crystalline



characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 8.7, 18.5, 22.6 and 26.6.

11. Crystalline



in accordance with claim 10 having the X-ray diffraction pattern substantially shown in Figure 3.

12. The compound



13. A process for making



,

the process comprising:

reacting



under dehydrating conditions with



to form



.

14. The process of claim 13 wherein the dehydrating conditions are azeotropic distillation with toluene.

15. A process of making



, the process comprising:

reacting



with  to form ,

wherein X is $CF_3SO_3^-$ or .

16. A process of making



, the process comprising:

reacting  with toluene to form 

17. A process of making



, the process comprising:

reacting



with lutidine and  to form



18. A process of making



, the process comprising reacting



with



2 H_2O

to form



, which is oxidized to



ethanolate

, which is further converted to



anhydrous

19. The process of claim 18 wherein the oxidation is accomplished using ozone.

20. The process of claim 18 wherein the oxidation is accomplished using ozone followed by Pinnick oxidation.

21. The process of claim 18 wherein the conversion of



ethanolate to



anhydrous is accomplished using methanol and water.

22. The process of claim 18 wherein the oxidation is accomplished using ozone followed by Pinnick oxidation, and the conversion of



ethanolate to



anhydrous is accomplished using methanol and water.

23. A process of making



, the process comprising reacting



with



to form



,



oxidizing



to form

ethanolate

which is further converted to



anhydrous

.

24. The process of claim 23 wherein the



and



are reacted in the presence of a base.

25. The process of claim 24 wherein the base is sodium tert-butoxide.

26. The process of claim 23 wherein the oxidation is accomplished using $RuCl_3$ and $NaIO_4$.

27. The process of claim 23 wherein the conversion of



ethanolate to



anhydrous is accomplished using methanol and water.

28. The process of claim 23 wherein the



and



are reacted in the presence of a base;

the oxidation is accomplished using $RuCl_3$ and $NaIO_4$; and

the conversion of



ethanolate



anhydrous

to is

accomplished using methanol and water.

29. The compound



ethanolate.

30. Crystalline



ethanolate.

31. Crystalline



ethanolate

characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 10.5, 18.2, 20.3, 21, 21.9 and 24.2.

32. Crystalline



ethanolate

in accordance with claim 31 having the X-ray diffraction pattern substantially shown in Figure 6.

33. The compound



34. Crystalline



35. Crystalline



characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 14.5, 14.3, 15.8, 17.7, 19.5 and 20.7.

36. Crystalline



in accordance with claim 35 having the X-ray diffraction pattern substantially shown in Figure 12.

37. A process of making



, the process comprising reacting



with an oxidizing agent and DABCO to form



and reacting



with an acid to form



38. The process of claim 37 wherein the oxidizing agent is ozone and the acid is hydrochloric acid.

What is claimed is:

1. A compound, wherein the compound is crystalline



2. The compound of claim 1, wherein the compound is crystalline anhydrous



3. The compound of claim 2, wherein the compound is characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 11.6, 12.4, 18.6, 19.0, 21.6 and 23.6.

4. The compound of claim 2, wherein the compound is characterized by the representative X-ray diffraction pattern shown in Figure 1.

5. The compound of claim 4, wherein the compound is characterized by the X-ray diffraction pattern shown in Figure 1.

6. The compound of any one of claims 2 to 5, wherein the compound is characterized by having a melting point as shown in Figure 8.

7. The compound of any one of claims 2 to 5, wherein the compound is characterized by the differential scanning calorimetry curve shown in Figure 8.

8. The compound of claim 1, wherein the compound is crystalline



of Form 1

characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 10.7, 11.2, 19.0, 21.5 and 23.0.

9. The compound of claim 8, wherein the compound is characterized by the X-ray diffraction pattern shown in Figure 4.

10. The compound of claim 1, wherein the compound is crystalline



of Form 2

characterized by a powder X-ray diffraction pattern comprising peaks at diffraction angle 2 theta degrees at approximately 12.9, 20.2 and 28.7.

11. The compound of claim 10, wherein the compound is characterized by the X-ray diffraction pattern shown in Figure 5.

12. A pharmaceutical composition comprising the compound of any one of claims 1 to 11 and a pharmaceutically acceptable excipient.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is a solid dosage form.

14. The pharmaceutical composition of claim 13, wherein the solid dosage form is a capsule, tablet, powder, or granule.

15. The pharmaceutical composition of claim 14, wherein the solid dosage form is a tablet.

16. The pharmaceutical composition of any one of claims 13 to 15, wherein the solid dosage form is for oral administration.

17. Use of a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject in need of said treatment.

18. The use of claim 17, wherein the cancer is selected from

(a) carcinomas, which comprise cancer of the bladder, breast, colon, rectum, kidney, liver, lung, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate and skin;

(b) hematopoietic tumors of lymphoid lineage, which comprise leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma;

(c) hematopoietic tumors of myeloid lineage, which comprise acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia;

(d) tumors of mesenchymal origin, which comprise fibrosarcoma and rhabdomyosarcoma, and other sarcomas, which comprise soft tissue sarcomas and bone sarcomas;

(e) tumors of the central and peripheral nervous system, which comprise astrocytoma, neuroblastoma, glioma and schwannomas;

(f) melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma, endometrial cancer, head and neck cancer, glioblastoma, malignant ascites, and hematopoietic cancers.

19. The use of claim 18, wherein the cancer is a hematopoietic tumor of lymphoid lineage.

20. The use of claim 18, wherein the cancer is soft tissue sarcoma.

21. The use of claim 18, wherein the cancer is breast cancer.

22. The use of claim 18, wherein the cancer is glioblastoma.

23. The use of claim 18, wherein the cancer is acute myeleogenous leukemia (AML).

24. The use of claim 18, wherein the cancer is melanoma.

25. The use of claim 18, wherein the cancer is myelodysplastic syndrome.

26. The use of any one of claims 18 to25, wherein the cancer is identified as p53wildtype (p53WT).

27. The use of any one of claims 18 to 25, wherein the medicament is to be used in combination with radiation therapy.

28. The use as claimed in claim 26, wherein the medicament is to be used in combination with radiation therapy.